Munchkin U.S. FDA process on hold

Synlait Milk Ltd · 1028 Heslerton Road, RD13 Rakaia, Canterbury, New Zealand · +643 373 3000 · www.synlait.com

SYNLAIT MILK LIMITED ANNOUNCEMENT NZX: SML
ASX: SM1
16 May 2019

M UNCHKIN U . S . FDA
PROCESS ON HOLD
The U.S. Food and Drug Administration (FDA) registration process required to launch Munchkin’s Grass
Fed™ infant formula in the U.S. has been put on hold.
Synlait (NZX: SML; ASX: SM1) has been informed that the clinical study has been put on hold to allow
Munchkin to explore other options in the U.S.
“Munchkin has not terminated its supply agreement with Synlait. For other markets where Grass Fed™ is
sold the relationship continues with business as usual,” says Synlait CEO, Leon Clement.
The development will not have a material impact on Synlait’s forecast infant formula volumes.

ENDS

For more information about Synlait visit www.synlait.com
or contact:
Jessica Thorn
Senior Communications Advisor, Synlait Milk
P: +64 3 373 3353
E: Jessica.thorn@synlait.com